Celgene Corporation (CELG) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for Celgene Corporation (NASDAQ: CELG):

  • 7/14/2017 – Celgene Corporation was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $149.76 price target on the stock.
  • 7/14/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $150.00 price target on the stock.
  • 7/11/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $160.00 price target on the stock.
  • 7/10/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Bank of America Corporation. They now have a $153.00 price target on the stock.
  • 7/6/2017 – Celgene Corporation was given a new $160.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “Acquisition of worldwide Rights to BeiGene,s (NASDAQ: BGNE, NC) excluding Asia, PD-1 inhibitor for solid tumors, BGB-A317, enhances CELG’s oncology portfolio and augments its immuno-oncology efforts.””
  • 7/6/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $139.00 price target on the stock.
  • 7/6/2017 – Celgene Corporation was given a new $148.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 7/6/2017 – Celgene Corporation was given a new $150.00 price target on by analysts at SunTrust Banks, Inc.. They now have a “buy” rating on the stock.
  • 7/4/2017 – Celgene Corporation was upgraded by analysts at Vetr from a “hold” rating to a “strong-buy” rating. They now have a $149.76 price target on the stock.
  • 6/30/2017 – Celgene Corporation was downgraded by analysts at BTIG Research from a “buy” rating to a “neutral” rating. They now have a $131.70 price target on the stock, up previously from $96.93.
  • 6/26/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at William Blair.
  • 6/22/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • 6/21/2017 – Celgene Corporation was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/16/2017 – Celgene Corporation was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $150.00 price target on the stock, up previously from $94.42. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 6/14/2017 – Celgene Corporation was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 6/14/2017 – Celgene Corporation was given a new $148.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 6/8/2017 – Celgene Corporation was given a new $148.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 6/7/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at Cann. They wrote, “The 2017 American Society of Clinical Oncology Meeting provided a venue for data presentations for a number of Celgene’s partnered programs, including enasidenib, BMCA CAR-T and JARCAR 017. Celgene had data on its wholly owned products, Revlimid and Abraxane.””
  • 6/6/2017 – Celgene Corporation was given a new $156.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 6/1/2017 – Celgene Corporation had its price target raised by analysts at Mizuho from $130.00 to $134.00. They now have a “buy” rating on the stock.
  • 5/24/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 5/24/2017 – Celgene Corporation had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
  • 5/23/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $152.00 price target on the stock.
  • 5/22/2017 – Celgene Corporation was given a new $148.00 price target on by analysts at Credit Suisse Group. They now have a “buy” rating on the stock.
  • 5/22/2017 – Celgene Corporation was given a new $156.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 5/22/2017 – Celgene Corporation was given a new $160.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 5/22/2017 – Celgene Corporation had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $162.00 price target on the stock.

Shares of Celgene Corporation (NASDAQ:CELG) traded up 0.22% during mid-day trading on Monday, reaching $134.87. 2,783,098 shares of the company’s stock traded hands. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $136.12. The company’s 50 day moving average is $121.46 and its 200 day moving average is $120.59. The company has a market cap of $105.31 billion, a P/E ratio of 50.65 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.47 by $0.21. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. The company’s revenue for the quarter was up 17.8% on a year-over-year basis. During the same period last year, the firm posted $1.32 earnings per share. On average, analysts predict that Celgene Corporation will post $7.28 EPS for the current fiscal year.

In other news, Director James J. Loughlin sold 18,500 shares of the firm’s stock in a transaction dated Monday, June 26th. The shares were sold at an average price of $133.57, for a total value of $2,471,045.00. Following the transaction, the director now directly owns 32,877 shares of the company’s stock, valued at $4,391,380.89. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rupert Vessey sold 4,785 shares of the firm’s stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $120.18, for a total transaction of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at $481,200.72. The disclosure for this sale can be found here. Over the last three months, insiders sold 237,005 shares of company stock worth $31,515,142. Insiders own 0.95% of the company’s stock.

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit